At a glance
- Originator Auckland Cancer Society Research Centre
- Class Antineoplastics
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Jul 1998 Profile reviewed
- 08 Jul 1998 No-Development-Reported for Cancer in New Zealand (Unknown route)
- 21 Mar 1995 Preclinical development for Cancer in New Zealand (Unknown route)